ArticleLeukemia2013

Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276.

J Schmidt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.